For nearly a century, Novo Nordisk has combined drug discovery with technology to turn science into treatments for the patients we serve.
The story begins with Nobel-prize winning physiologist Dr. August Krogh and his belief that anyone who suffered from diabetes, including his wife Marie, should have access to insulin.
Inspired by his wife, Dr. Krogh founded Nordisk Insulinlaboratorium in 1923 and marketed the first insulin for patients. Marie was the first beneficiary – and our first patient.
Two years later, another company – Novo Terapeutisk Laboratorium – was born and began producing "Insulin Novo" and a unique syringe.
Over the decades, these 2 companies grew to be global leaders in insulin production and other areas. In 1989, Novo and Nordisk joined forces to become Novo Nordisk.
Our founders could not have foreseen the global pandemic we face today. But our mission remains the same: to provide care and treatment for people with diabetes around the world and to put patient needs at the center of everything we do.
As a world leader in diabetes care, Novo Nordisk’s greatest contribution to society is our commitment to bringing value to patients and healthcare professionals through innovation. However, diabetes is not our only focus. Our innovative work in hemophilia, growth hormone disorders, and women’s health is driven by this same commitment.
Our global vision is to defeat diabetes in our lifetime - a truly unique and ambitious endeavor, but we believe that by actively promoting collaboration between all parties in the healthcare system, we can achieve our common goals.
To learn more, please visit us at novonordisk-US.com.
